Study Details
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate
Clinicaltrials.gov ID
Astellas Study ID
5094-CL-0102
EudraCT ID
2015-004562-28
Condition
Rheumatoid Arthritis
Phase
Phase 1
Age
18 years - 65 years
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Feb 2016 - Sep 2017
Masking
Double (Participant, Investigator)
Enrollment number
30
A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site PL48004
Nowa Sol, Poland, 67-100
Site US10008
Debary, United States, 32713-1818
Site US10002
Anniston, United States, 36207
Site US10004
Jacksonville, United States, 32216
Site US10010
Memphis, United States, 38119
Site PL48003
Warszawa, Poland, 00-660
Site PL48007
Stalowa Wola, Poland
Site PL48006
Lodz, Poland, 91-347
Site PL48011
Krakow, Poland, 31-637
Site PL48001
Lublin, Poland, 20-582
Site US10001
Dallas, United States, 75231
Site US10003
Duncansville, United States, 16635
Site PL48009
Elblag, Poland, 82-300
Site PL48008
Wroclaw, Poland, 50-556
Site US10009
Miami Lakes, United States, 33014